IRVINE, Calif., and BURLINGTON, Mass., July 18, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, and LeMaitre Vascular, Inc.

--Application Included Successful Viral Inactivation Study that Enhances PeriPatch's Position as Tissue of Choice for Third-Party Implantable Cardiovascular Products-- --CE Marking Will Enable LeMaitre Vascular to Sell its PeriPatch-Based XenoSure(R) Product in Europe-- VANCOUVER, Feb.

--Vascular Device Leader LeMaitre Vascular to Distribute Neovasc's Biological Vascular Strips in the U.S. and Europe, With Option to Purchase the Product Line-- VANCOUVER, Jan. 26 /PRNewswire-FirstCall/ - Neovasc Inc.

BURLINGTON, Mass., Dec. 21 /PRNewswire-FirstCall/ -- LeMaitre Vascular, Inc.